Pranoprofen is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory activity; it is clinically used to treat dry eye. Pranoprofen inhibits COX-1 and COX-2. Pranoprofen inhibits production of sodium urate-induced superoxide, prostaglandin E2 (PGE2), and β-glucuronidase.
| Cas No. | 52549-17-4 |
|---|---|
| Purity | ≥98% |
| Formula | C15H13NO3 |
| Formula Wt. | 255.27 |
| Chemical Name | α-Methyl-5H-[1]benzopyranol[2,3-b]pyridine-7-acetic acid |
| IUPAC Name | 2-(5H-chromeno[2,3-b]pyridin-7-yl)propanoic acid |
| Synonym | Y-8004; Niflan |
| Melting Point | 182-183°C |
| Appearance | White or Light yellow crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | P6802 Info Sheet PDF |
|---|
Chen J, Dong F, Chen W, et al. Clinical efficacy of 0.1% pranoprofen in treatment of dry eye patients: a multicenter, randomized, controlled clinical trial. Chin Med J (Engl). 2014 Jul;127(13):2407-12. PMID: 24985574.
Aratani H, Iwahisa Y, Imayoshi T, et al. Mechanism of the inhibitory effect of pranoprofen on sodium urate crystal-induced inflammation. Nihon Yakurigaku Zasshi. 1987 Mar;89(3):139-44. PMID: 3556352.
